Rearrangements and aberrant expression of the retinoic acid receptor alpha gene in acute promyelocytic leukemias by unknown
Acute promyelocytic leukemia (APL;t M3 of the FAB
1 .1 classification) is a distinct, well-characterized clinical and
morphological subtype of acute myeloid leukemia (AML) (1,
2). It is cytogenetically distinguished by a reciprocal chro-
mosome 15;17 translocation, which is present in 70-90% of
cases and never seen in other AMLs or other types of malig-
nancy (3, 4). Although the high frequency and specificity of
the t(15;17), and the fact that it is often the only karyo-
typic aberration present (4), is strong evidence that it plays
a crucial role in the pathogenesis ofAPL, the gene(s) directly
involved in the chromosome 15 and 17 breakpoints have never
been identified. We have previously shown that the APL chro-
mosome 17 breakpoint lies between the c-erbB-2 and the
retinoic acid receptor a (RARci) loci (5). We report here the
findings of RARct gene rearrangement and aberrant expres-
sion in APLs.
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Summary
Although acute promyelocytic leukemias (APLs) are consistently associated with a reciprocal
chromosome 15;17 translocation, the gene(s) directly affected by the breakpoints have never been
isolated. The chromosome 17 breakpoint maps to near the retinoic acid receptor a (RARa)
locus. Investigation of20 APLs and a large series ofother neoplastic patients and normal controls
revealed RARa gene rearrangements and aberrant transcripts only in the APL cases. These findings
suggest that the RARce gene is involved in the APL chromosome 17 breakpoint, is implicated
in leukemogenesis, and could be used as a marker for identifying leukemic promyelocytes.
MolecularStudies.
￿
The K/S, IT, and P/R RARct cDNA probes
were obtained by subcloning portions of the p63 plasmid (6) in
'Abbreviations used in this paper: ALL, acute lymphoblastic leukemia;
AML, acutemyeloid leukemia; APL, acutepromyelocytic leukemia; BM,
bone marrow; RARa, retinoic acid receptor a.
the pGEM-3 vector. The K3 probe is a KpnI/BamHI 1.8-kb
genomic fragment derived from the RARa-Fixa1 phage, isolated
from a X-FixII human genomic library (Stratagene, La Jolla, CA)
(unpublished data). It includes the intron located between the
RARa exons 281-430 and 431-574 (exon nucleotide positions refer
to the RARot cDNA sequence of reference 6), Southern and
Northern blot analyses were performed according to established
procedures (7).
Cytogenetic Analysis.
￿
Chromosome preparations were obtained
from unstimulated bone marrow (BM) cultures as previously de-
scribed (5).
Results
The RARct KIS cDNA Probe Hybridizes to Extrafragments
in 13 of20 APL DNAs. High molecular weight DNA was
extracted from the blasts of 20 leukemia patients who met
all the morphological criteria for the FAB M3 classification
(2). 18 displayed the typical t(15;17), and two had a normal
karyotype (Table 1). DNAs were digested with the EcoRl,
HindIII, or BamHI restriction enzymes and hybridized to
DNA probes representative of different portions ofthe RARce
cDNA in Southern blot experiments (probes are diagramati-
cally shown in Fig. 1). The K/S probe representative of the
5' end of the RARet p63 cDNA revealed additional hy-
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line pattern with one (four cases), two (seven cases), or all
three (two cases) of the restriction enzymes used (Fig. 2).
The additional fragments were of a different size in each case
(Table 1) . No deviation from the germline configuration was
seen in any case with either the RARcx IT or P/R cDNA
probes, which contain the intermediate or the 3' portions
of the RARa p63 cDNA, respectively (not shown) .
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G, germline hybridization fragments; R, rearranged fragments (kilobase length is given between parentheses). Numbers in the Northern column
indicate the length of RARa transcripts (the typical 3.8- and 2.8-kb transcripts are underlined) .
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TheKIS-hybridizingExtrafragmentsAreNot the Consequence
ofGenetic Variation. 19 DNAs from normal PBL and 45 non-
APL samples were digested with the EcoRI, HindIII, or
BamHI restriction enzymes and hybridized to the K/S DNA
probe. All cases showed the germline K/S hybridization pat-
tern with all three restriction enzymes (not shown). In addi-
tion, DNA was extracted from the BM cells of two APL
patients (3MGa and 14MSa) who had entered morpholog-
Mono
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Figure 1.
￿
RARa DNAprobes.
A near full-length RARct cDNA
is shown in the top line (1-2940)
(10). Theblockis a schematic rep-
resentation of the coding region.
TheDNA(C)andretinoic acid(E)
binding domains are shown. A
limitedrestriction map of the p63
plasmid (6) used to generate the
RARa probes is shown in the
middle line. The broken line indi-
cates that thesequenceof theregion
hasnotbeen reported. Numberson
thebarsbelowindicate thesequence
limits ofeach probewith respect to
the RARa cDNA.
Table 1.
APLs
Synthesis of Cytogenetic,
Cytogenetic
and Southern and Northern
E
Blot Results in APL Cases
Southern
H B Northern
1MPa t15;17 G G G ND
2MGu t15;17 G G G 4.0; _3 .8; 3.5; _2.8
3MGa t15;17 R(13.7) R(5.5) G ND
4MCh 46,XX G G G ND
5MFe t15;17 R(16.5) R(23) ND ND
6MMa tl5;17 G R(17) ND 4.4; _3.8; _2.8
7MPi t15;17 G G G 4.0; 3.5 ; 2.8
8MRo t15;17 G G G 4.0; _3.8 ; 3.5; 2.8
9MSp t15;17 G G R(16.5) ND
10MMO t15;17 G R(9) R(9.5) 4.4; _3.8; _2.8
11MGu t15;17 G R(18) G 4.0; 3.5
12MVa t15;17 G G G ND
13MTr t15;17 R(11 .5) R(6.6) R(7) ND
14MSa t15;17 G R(16) G 4.4; _3.8; 2.8
15MPa t15;17 R(16.4) R(6) G 4.0; _3.8; 3.5; 2 2 8
16RDe tl5;17 G G G ND
17TGp t15;17 R(3.6) R(7.5) G ND
18RLa t15;17 R(6) G R(9.4) ND
19T48 t15;17 R(13.3) R(8.5) G ND
20PRe 46,XY R(9.7) R(6.5) R(6.7) NDical remission after conventional chemotherapy. TheseDNAs,
and DNAs extracted from blasts of the same patients before
remission, were digested with the HindIII restriction enzyme,
hybridized to the K/S probe, and compared . The results
showed that the K/S extra-fragments seen in the APL blasts
had disappeared in one case (3MGa) and become fainter in
the other (14MSa) (Fig . 3) . Taken together, these data indi-
cate that the K/S extra-fragments are not the consequence
of RFLPs, but of somatic mutations that had occurred in
the APL blasts . In the 14MSa case, where the K/S extra-
fragment was less intense after chemotherapy, promyelocytes
Figure 3 .
￿
Southern blot analysis of
the RARa gene in two APL cases
at diagnosis and during remission.
DNAs from placenta (P), BM APL
blasts of two patients (14MSa, 14 ;
3MGa, 3), and BM cells from the
sametwo patientsafterchemotherapy
(14, 3) were digested with theHindIIl
restriction enzyme and hybridized to
theK/Sprobe . Amorous indicateRARa-
rearranged bands.
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Figure 2 .
￿
Southernblot analysis
ofthe RARoi gene in APLs.DNAs
from 20 APLs were digested with
EcoRl (A), HindlIl (B), or BamHl
(C) restrictionenzymes and hybrid-
ized to the K/S probe. The cases
are identified above the lanes by the
same numbers as used in Table 1 .
P, placentaDNA . Arrows indicate
RARa-rearranged bands. Molec-
ular weight markers are indicated
at the left of each panel.
may have persisted in the BM despite the diagnosis of mor-
phological remission. It is well known that, due to the
difficulty of establishing whether promyelocytes are normal
or leukemic, it is far from easy to accurately assess remission
in APL (8) .
TheKIS-hybridizing ExtrafragmentsAre the Consequence of
RARai Gene Rearrangements. The RARot gene is a member
of the steroid and thyroid hormone receptor family (9) . The
members of this family share certain structural features : they
contain the highly conserved domain that mediates receptor
binding to specific sequences ofDNA in target genes and
the less conserved domain required for ligand binding. As
a consequence, the K/S probe, which includes the DNA
binding domain, hybridizes to other than RARci fragments
in Southern blot experiments (10) . To exclude that the extra-
bands seen in theAPL blasts were due to crosshybridizations
of the K/S probe, three APL DNAs were hybridized to the
K3 probe, which includes intron sequences of the RARa
locus (see Materials and Methods for a description of the K3
probe) . The K3 probe hybridized to a single EcoRI fragment
in placenta DNA and to extra-fragments in all three APL
EcoRI-digested DNAs (Fig. 4) . Note that the K3 EcoRI-
hybridizing extra-fragments were of the same size as theK/SEcoRI extra-fragments in all three APL cases (Figs. 2 and
4) . We conclude that RARot rearrangements are responsible
for the K/S-hybridizing extra-fragments.
RARot Gene Is Aberrantly Expressed in allAPLs.
￿
To de-
termine whether the rearrangements of theRARa locus in-
terfere with its expression pattern, Northern blot experiments
were performed on RNAs extracted from APL blasts. When
the I/T and K/S probes were hybridized with RNAs from
one AM1rM6 and one acute lymphoblastic leukemia (ALL)
case, the typical RARa double transcript (3.8 and 2.8 kb)
was seen (see Fig. 5 for IT hybridizations) (11) . However,
when theRNAs from eight APL cases were hybridized with
the same two probes, the two typical RARci transcripts ap-
peared at an intensity that varied both within and between
samples in seven cases . Neither transcript was detected in one
case (11MGu) . All eight cases exhibited one or two RARa-
aberrant transcripts of three different sizes : 4.4 kb in three
cases (6MMa, 10 MMo, 14MSa) ; and 4.0 and 3.5 kb in
five (2MGu, 7MPi, 8MRo, 11MGu, 15MPa) (Fig . 5 and
Table 1) . The eight APL cases included two (2MGu, 7MPi)
that carried the germline configuration of the RARu gene
(Table 1) .
RARa-aberrant Transcripts Are Specific toAPLs .
￿
To inves-
tigate the specificity of the aberrant transcripts, the RARce
expression pattern was analyzed in a variety ofnon-APL RNAs
that included both normal (granulocytes, monocytes, lym-
phocytes, mesothelial cells, amnion cells) and neoplastic cells
(21 AMLs, five chronic myelogenous leukemias, six ALL,
one chronic lymphoidleukemia, one Burkitt lymphoma, one
Hodgkin lymphoma, two lung cancers, two brain tumors,
one cervix cancer, and one bladder cancer) . Only the typical
3.8- and 2.8-kb transcripts were detected in all cases (not
shown) .
Discussion
The RARci locus maps in the proximity of the chromo-
some 17 breakpoint of the APIrspecific t(15;17) (5, 12) . How-
ever, the relationship between the chromosome 17 breakpoint
and theRARoi locus is notknown . 13 of the 20APLDNA
samples analyzed bore rearrangements of the RARoe gene,
and eight of eight RNA samples showed aberrant RARa
transcripts. These findings provide insights into both themo-
lecular architecture of the t(15;17) and the pathogenesis of
APLs .
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Figure 4.
￿
Hybridization of the
K3 genomic RARot probe to
three APL cases . Three APL
(19T48, 19 ; 20PRe, 20; 17TGp,
17) and placental (P) DNAs were
digested with the EcoRI restric-
tion enzyme and hybridized to the
K3 genomic RARa probe.
Figure 5.
￿
RARoi gene expression patterns in APLs.RNA samples from
BM blasts of eight APLs, one AML-M6, and oneALL case were analyzed
by Northern blotting using the IT probe. Both PBL andBM blasts were
analyzed forpatient2MGu (2PB,2BM. The patient numbers are the same
as those used in Table 1. Ribosomal RNAs (28S and 18S) are given as
size markers. The estimated length (3 .8 and 2 .8 kb) oftheRARa typical
double transcript is also given. Arrows indicate aberrant RARci transcripts .
As 12 of the 13 rearranged RARot alleles were identified
in APLs with the t(15;17), the rearrangements could be in-
dicative of a breaksite within, or in the proximity of, the
RARci locus . The fact that the remaining case had a normal
chromosome 17 at cytogenetic analysis does not contradict
this proposal, since the RARct rearrangement could be as-
sociated with submicroscopic chromosome 17 aberrations,
similar to those encountered in chronic myeloid leukemias
that bear bcr gene rearrangements in the absence of the typ-
ical 9;22 chromosome translocation (13) . Although noRARoi
rearrangements were detected in six APLs with the t(15;17),
they could have occurred in regions ofthe gene not explored
by presently available RARotDNA probes . The finding of
aberrant RARa transcripts in everyAPL case examined, in-
cluding two with no RARu rearrangements, supports the
hypothesis that structural abnormalities occur in the RARa
gene of allAPLs . The physiological function of the RARce
gene product supports the hypothesis that such abnormali-
ties are involved in the pathogenesis of APLs . RARac is an
intracellular receptor that functions to regulate gene expres-
sion in response to the binding ofretinoic acid (RA) (6, 10) .
RA exerts profound effects on embryonic development and
cell differentiation in many systems (9), and is also a potent
inducer of the differentiation ofmyeloid leukemia blasts (14),
including APL (15).
Finally, the combined Southern and Northern blot anal-
yses of the RARce gene provides us with a molecular marker
for neoplastic promyelocytes. The clinical implications ofsuch
a marker are obvious, since it would both allow neoplastic
promyelocytes to be unambigously distinguished from normal
promyelocytes at diagnosis, andwould permit the monitoring
ofAPL cases during induction chemotherapy ; neither ofwhich
can be done by presently available methods .
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